Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Cigarette Smoke and Vaping May Reprogram Blood-Forming Stem Cells, Study Finds
    4 September 2026

    Cigarette Smoke and Vaping May Reprogram Blood-Forming Stem Cells, Study Finds

    Cigarette smoke and e-cigarette aerosol may have lasting effects on the body's immune system and blood-forming cells, according to a new study by researchers at the University of California, Irvine. The research found that exposure to cigarette smoke and e-cigarette vapor altered immune responses and affected hematopoiesis, the process through which blood cells are produced. The findings raise concerns about the potential long-term consequences of both conventional smoking and vaping on immune function and the hematopoietic system.

  • FDA Warns Fresenius Medical Care Over Leaking Dialysis Bags and Manufacturing Control Failures
    4 September 2026
    FDA Warns Fresenius Medical Care Over Leaking Dialysis Bags and Manufacturing Control Failures

    The U.S. Food and Drug Administration (FDA) has issued a warning letter to Fresenius Medical Care AG & Co. KGaA, citing significant Current Good Manufacturing Practice (CGMP) violations at its Ogden, Utah manufacturing facility.

  • CDSCO Cancels Cosmetic Import Registrations of Skintl Enterprises Over Multiple Violations
    3 September 2026
    CDSCO Cancels Cosmetic Import Registrations of Skintl Enterprises Over Multiple Violations

    The Central Drugs Standard Control Organization (CDSCO) has cancelled three registration certificates issued to M/s Skintl Enterprises Pvt. Ltd., citing multiple violations related to the import, labelling and handling of cosmetic products. The cancellation order was issued by the Central Licensing Authority on 24 August 2026.

  • FDA Raises Fresh Safety Concerns Over Unapproved GLP-1 Weight-Loss Drugs
    3 September 2026
    FDA Raises Fresh Safety Concerns Over Unapproved GLP-1 Weight-Loss Drugs

    The U.S. Food and Drug Administration (FDA) has issued a detailed warning about the risks associated with unapproved and compounded GLP-1 drugs being used for weight loss, highlighting concerns related to product quality, dosing errors, counterfeit medicines and improper storage.

  • Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations
    3 September 2026
    Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations

    Gland Pharma Limited has announced the successful conclusion of a routine Good Manufacturing Practice (GMP) inspection conducted by the United States Food and Drug Administration (USFDA) at its facilities in Visakhapatnam.

    The inspection was carried out at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam. The regulatory inspection commenced on August 24, 2026, and concluded on September 1, 2026.

  • VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study
    3 September 2026
    VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study

    A new study published in Acta Clinica Belgica has found that vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) can produce substantial tumor shrinkage in patients with metastatic clear-cell renal cell carcinoma (ccRCC) involving the pancreas.

  • Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
    3 September 2026
    Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
    A new economic evaluation published in JAMA Dermatology has found that adalimumab 40 mg administered weekly offers the most consistent balance between treatment effectiveness and cost among currently approved monoclonal antibody therapies for hidradenitis suppurativa (HS).
  • ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines
    3 September 2026
    ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines

    The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop new technologies aimed at making individualized, RNA-based genetic medicines faster and more accessible.

    The initiative is part of ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which could receive up to 125 million USD in research and development funding. The program seeks to establish an automated, distributed manufacturing network capable of producing genetic medicines on demand and closer to the point of care.

  • Dry Eye Remains an Overlooked Menopause Symptom, Bausch and Lomb Survey Reveals
    2 September 2026
    Dry Eye Remains an Overlooked Menopause Symptom, Bausch and Lomb Survey Reveals
    Dry eye is significantly underrecognized as a symptom associated with perimenopause and menopause, according to findings from a new survey conducted by Bausch + Lomb. The survey highlights a substantial awareness gap among women and points to the need for greater attention to eye health during this stage of life.
  • Novartis’ Remibrutinib Delivers Positive Phase III Results in Relapsing Multiple Sclerosis
    2 September 2026
    Novartis’ Remibrutinib Delivers Positive Phase III Results in Relapsing Multiple Sclerosis

    Novartis has announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials evaluating remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with relapsing multiple sclerosis (RMS).

    The investigational therapy met the primary endpoint in both trials, demonstrating a statistically significant reduction in annualized relapse rate (ARR) compared with teriflunomide. The studies also reported favorable results across key secondary endpoints, including measures of inflammatory brain lesions seen on MRI.

Subscribe to Pharma News